Skip to Content
Stock Analyst Update

Should Investors Leave P&G Shares on the Shelf?

Inflation and supply chain shortages put pressure on the wide-moat company.

Mentioned:

Despite unrelenting cost pressures and shortages across its supply chain (particularly as it pertains to labor), wide-moat Procter & Gamble (PG) delivered impressive fiscal 2022 second-quarter performance. Organic sales popped 6% versus a year ago (on top of an 8% jump last year), driven by higher prices and stepped-up volumes (each of which contributed 3%). And although the firm realized a compression in profitability (with gross and operating margins down 400 and 250 basis points, respectively, to 49.1% and 24.7%), we don’t believe this erosion reflects cracks in its armor. Rather, pronounced inflationary headwinds (a 400-basis-point drag to gross margin in the period) combined with higher freight costs (a 60-basis-point hit) were the primary culprits, factors that are plaguing firms across a swath of industries given the breadth of the cost increases. While we don’t expect these higher costs to abate near term--in line with P&G’s expectations for commodities and freight to serve as a $2.8 billion headwind in fiscal 2022, up from its $2.3 billion outlook three months earlier--we think the firm remains squarely focused on unearthing efficiencies in its underlying business (an 80-basis-point benefit in the quarter at the gross margin line) and raising prices (a 130-basis-point boost in the quarter) to offset this barrage of challenges, which we view as prudent.

Management edged up its fiscal 2022 sales growth guidance to 3%-4% (from 2%-4%) but held the line on its aims for 6%-9% EPS growth, which aligns with our prior outlook (3.9% and 7.0%, respectively). Although we are unlikely to alter our near- or long-term forecast, our $118 fair value estimate should see a low-single-digit increase, spurred by time value and our revised expectation for the statutory U.S. corporate tax rate to remain at 21%. However, shares traded higher around 4% on the news; at more than a 33% premium to our intrinsic valuation, we think investors should remain on the sidelines.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Erin Lash does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.